Allison Hagerman net worth and biography

Allison Hagerman Biography and Net Worth

Chief Technology Officer of Oncolytics Biotech

A professional engineer focused on biotechnology, Allison Hagerman joined Oncolytics in 2010 and has been integral to the progress of its product development program ever since. Prior to being appointed as Vice President of Product Development, Ms. Hagerman was the Director, Manufacturing and Engineering from 2013-2017 and Project Manager from 2010-2013, during which time she led the process performance qualification for pelareorep drug substance. Ms. Hagerman is a Professional Engineer (P.Eng., APEGA) and Project Management Professional (PMP, PMI). She holds a Master of Biomedical Technology (MBT) degree from the University of Calgary, and B.Sc. degrees in both Chemical Engineering and Biological Sciences. She is an accomplished equestrian and spends her spare time on horseback.

What is Allison Hagerman's net worth?: The estimated net worth of Allison Hagerman is at least $68.39 thousand as of February 12th, 2026. Ms. Hagerman owns 79,842 shares of Oncolytics Biotech stock worth more than $68,393 as of August 28th. This net worth estimate does not reflect any other assets that Ms. Hagerman may own. Learn More about Allison Hagerman's net worth.
How do I contact Allison Hagerman?: The corporate mailing address for Ms. Hagerman and other Oncolytics Biotech executives is 1167 Kensington Crescent Suite 210, Calgary A0, T2N 1X7. Oncolytics Biotech can also be reached via phone at (403) 670-7377 and via email at [email protected]. Learn More on Allison Hagerman's contact information.
Has Allison Hagerman been buying or selling shares of Oncolytics Biotech?: Allison Hagerman has not been actively trading shares of Oncolytics Biotech during the last quarter. Most recently, on Thursday, February 12th, Allison Hagerman bought 10,000 shares of Oncolytics Biotech stock. The stock was acquired at an average cost of $0.83 per share, with a total value of $8,300.00. Following the completion of the transaction, the vice president now directly owns 115,059 shares of the company's stock, valued at $95,498.97. Learn More on Allison Hagerman's trading history.
Are insiders buying or selling shares of Oncolytics Biotech?: During the last year, Oncolytics Biotech insiders bought shares 14 times. They purchased a total of 404,282 shares worth more than $363,231.56. The most recent insider tranaction occured on March, 12th when CEO Jared Kelly bought 5,050 shares worth more than $4,848.00. Insiders at Oncolytics Biotech own 0.1% of the company. Learn More about insider trades at Oncolytics Biotech.
Information on this page was last updated on 3/12/2026.

Allison Hagerman Insider Trading History at Oncolytics Biotech

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/12/2026	Buy	10,000	$0.83	$8,300.00	115,059

Allison Hagerman Buying and Selling Activity at Oncolytics Biotech

Oncolytics Biotech Company Overview

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Today's Range

Now: $0.86

$0.82

$0.86

50 Day Range

MA: $0.85

$0.75

$0.96

2 Week Range

Now: $0.86

$0.73

$1.51

Volume

671,581 shs

Average Volume

1,275,658 shs

Market Capitalization

$109.39 million

P/E Ratio

N/A

Dividend Yield